U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-QSBA
(Mark One)
X Quarterly report under Section 13 or 15(d) of the Securities
Exchange act of 1934
For the quarterly period ended March 31, 1996
__ Transition report under Section 13 or 15(d) of the Exchange Act
For the transition period from to
Commission file number Securities Act Registration No. 33-75276
Creative Medical Development, Inc.
(Exact Name of Small Business Issuer as Specified in its Charter)
Delaware 68-0314381
(State or Other Jurisdiction of (I.R.S. Employer Identification NO.)
Incorporation or Organization)
870 Gold Flat Road, Nevada City, CA 95959
(Address of Principal Executive Offices)
(916) 265-8222 (Issuer's Telephone Number, Including Area Code)
(Former Name, Former Address and Former Fiscal Year,
if Changed Since Last Report)
Check whether the issuer: (1) filed all reports required to be
filed by Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the
past 90 days.
Yes X No
APPLICABLE ONLY TO ISSUERS INVOLVED IN
BANKRUPTCY PROCEEDINGS DURING THE
PRECEDING FIVE YEARS
Check whether the registrant filed all documents and reports
required to be filed by Section 12, 13 or 15(d) of the Exchange Act after
the distribution of securities under a plan confirmed by a court.
Yes No
APPLICABLE ONLY TO CORPORATE ISSUERS
State the number of shares outstanding of each of the issuer's
classes of common equity, as of the latest practicable date:
2,046,159 Common Shares and 810,000 Series A Preferred Shares all at $.01
par value were outstanding as of April 30, 1996.<PAGE>
OTHER INFORMATION - PART II
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
EX-27
(b) Reports on Form 8-K
One filed May 1, 1996, reporting the closing of the sale
of Assets to Gish Biomedical, Inc. on April 17, 1996.
SIGNATURES
In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Creative Medical Development, Inc.
Registrant
Dated: August 15, 1996 Ronald J. Gangemi,
Chief Executive Officer
Dated: August 15, 1996 John E. Hart
Treasurer
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS FOR THE QUARTERS ENDED MARCH 31, 1995 AND MARCH 31,1996
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS
</LEGEND>
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> SEP-30-1996
<PERIOD-END> MAR-31-1996
<CASH> 0
<SECURITIES> 0
<RECEIVABLES> 121,196
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 121,196
<PP&E> 2,013,001
<DEPRECIATION> 0
<TOTAL-ASSETS> 2,134,197
<CURRENT-LIABILITIES> 1,064,181
<BONDS> 0
0
8,100
<COMMON> 20,461
<OTHER-SE> (164,044)
<TOTAL-LIABILITY-AND-EQUITY> 2,134,197
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 75,969
<INCOME-PRETAX> (98,652)
<INCOME-TAX> 0
<INCOME-CONTINUING> (30,069)
<DISCONTINUED> (68,583)
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (98,652)
<EPS-PRIMARY> (.05)
<EPS-DILUTED> (.05)
